Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787410 | 0.74 | NPSR1 (0.62) | ALDH1A1NPSR1LMNAPOLBKDM4E | |
| SCHEMBL1788116 | 0.73 | ALDH1A1 (0.57) | ALDH1A1NPSR1LMNAPOLBKDM4E | |
| SCHEMBL1786624 | 0.72 | NPSR1 (0.56) | ALDH1A1NPSR1LMNAKDM4EKMT2A | |
| SCHEMBL1787409 | 0.72 | SMN1; SMN2 (0.47) | ALDH1A1NPSR1LMNAKDM4EKMT2A | |
| SCHEMBL13721019 | 0.70 | NPSR1 (0.44) | ALDH1A1NPSR1LMNAKDM4EMAPK1 | |
| SCHEMBL13721812 | 0.69 | LMNA (0.40) | ALDH1A1NPSR1LMNAKDM4EMAPK1 | |
| SCHEMBL1787363 | 0.69 | TSHR (0.61) | ALDH1A1LMNAKDM4EKMT2AL3MBTL1 | |
| SCHEMBL1786845 | 0.68 | NPSR1 (0.56) | ALDH1A1NPSR1POLBKDM4EKMT2A | |
| SCHEMBL13720590 | 0.68 | TP53 (0.41) | ALDH1A1KDM4EKMT2APTGS2MEN1 | |
| SCHEMBL1788291 | 0.68 | BCAT1 (0.42) | ALDH1A1KDM4EMAPK1KMT2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1644/4885NPSR1 505/4885LMNA 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.